Casimersen

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameCasimersen
Drug Alias NameAmondys 45AMONDYS 45SRP-4045
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionDystroglycan stimulantsDystrophin pre-mRNA modulators
TargetsDystroglycanDystrophin pre-mRNA
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsMuscular Dystrophy, Duchenne
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/02/25
Country/TerritoryCzechiaBelgiumBulgaria +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSarepta Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSarepta Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeM09AX
Related LinksWikipediaDrugBankKEGG